Targeted next-generation-sequencing (NGS) panels have largely replaced Sanger sequencing in clinical diagnostics. They allow for the detection of copy-number variations (CNVs) in addition to single-nucleotide variants and small insertions/deletions. However, existing computational CNV detection methods have shortcomings regarding accuracy, quality control (QC), incidental findings, and user-friendliness. We developed panelcn.MOPS, a novel pipeline for detecting CNVs in targeted NGS panel data. Using data from 180 samples, we compared panelcn.MOPS with five state-of-the-art methods. With panelcn.MOPS leading the field, most methods achieved comparably high accuracy. panelcn.MOPS reliably detected CNVs ranging in size from part of a region of interest (ROI), to whole genes, which may comprise all ROIs investigated in a given sample. The latter is enabled by analyzing reads from all ROIs of the panel, but presenting results exclusively for user-selected genes, thus avoiding incidental findings. Additionally, panelcn.MOPS offers QC criteria not only for samples, but also for individual ROIs within a sample, which increases the confidence in called CNVs. panelcn.MOPS is freely available both as R package and standalone software with graphical user interface that is easy to use for clinical geneticists without any programming experience. panelcn.MOPS combines high sensitivity and specificity with user-friendliness rendering it highly suitable for routine clinical diagnostics.
INTRODUCTION
For many disease genes, comprehensive mutation analysis in clinical diagnostics includes the detection of (1) small sequence alterations, such as substitutions, deletions, duplications, and insertions of one or a few nucleotides, and (2) copy-number variations (CNVs), which are often defined as deletions or duplications larger than 50 bp (Alkan, Coe, & Eichler, 2011) . CNVs may affect one or more genes of interest where either the whole gene or only one or more exons thereof are altered. Previously, Sanger sequencing was used for routine detection of small sequence alterations. If no disease-causing mutation was found by these means, multiplex ligation-dependent This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. probe amplification (MLPA) (Schouten et al., 2002) , quantitative PCR (Charbonnier et al., 2000) , or array-based techniques (Komura et al., 2006) were applied in a second step to identify (intragenic) CNVs. Targeted next-generation-sequencing (NGS) panels have now replaced Sanger sequencing in many diagnostic laboratories. They provide several advantages over whole-genome sequencing (WGS) and wholeexome sequencing (WES): since only a limited number of genes is targeted, data can be generated and stored on smaller machines, which makes NGS panels more flexible as well as time-and cost-effective.
Furthermore, higher accuracy is achieved due to deeper coverage (de Leeneer et al., 2015; Lin et al., 2012; Meder et al., 2011; Weiss et al., 2013 1. Compromise between sensitivity and specificity: Although the sensitivity of CNV detection methods is improving, this is often achieved at the expense of a high number of false-positive findings (Pugh et al., 2016) .
Poor quality control (QC):
Variations of the DNA quality, the library preparation, or the sequencing process itself can lead to differences in read count (RC) characteristics between samples. Therefore, the RCs of the affected samples cannot be compared. Further, the coverage of regions of interest (ROIs) can be low due to high GC content or sequence characteristics that affect either enrichment or mappability of reads. RCs and gene assignment can also be highly variable in ROIs with a highly homologous pseudogene. These issues influence the read depth and prevent reliable CN detection in these ROIs. QC that filters out low-quality samples and
ROIs is therefore an essential step, especially in clinical diagnostics (Johansson et al., 2016) . However, if too many samples or ROIs are excluded, a method may cease to be useful.
3.
Low sensitivity in the detection of small or large CNVs: Methods perform well at detecting either small CNVs that affect only (part of) one ROI or large CNVs that encompass all ROIs of a gene. However, in a clinical setting, both is required.
4.
Risk of incidental findings: Since many gene panels are designed to cover several different disease types at once, incidental findings become problematic in clinical interpretation and reporting. Current CNV detection methods do not provide a satisfactory solution that limits the analysis report to genes of interest without diminishing the ability to detect large CNVs that cover all ROIs of the one gene to be analyzed.
5.
Low user-friendliness: While commercial products usually provide graphical user interfaces to facilitate analysis, most noncommercial methods require at least some basic programming experience, which often discourages clinical laboratories from using them.
With the aim to address all these shortcomings, we developed panelcn.MOPS, a pipeline for detecting CNVs in targeted NGS panel data that builds upon cn.MOPS (Copy Number estimation by a Mixture Of Poissons) (Klambauer et al., 2012 ) (see Fig. 1 ). The superior performance of cn.MOPS on WGS and WES data has already been demonstrated (Guo et al., 2013; Klambauer et al., 2012) . Specifically, cn.MOPS has been used to detect CNVs in the Taiwanese Han and Qatari populations (Fakhro et al., 2015; Lin, Tseng, Jeng, & Sun, 2014) , in individuals with intellectual disability (Schuurs-Hoeijmakers et al., 2013) , and in patients with early-onset neuropsychiatric disorders (Brand et al., 2014 In this study, we present the newly developed panelcn.MOPS pipeline and compare it against five state-of-the-art CNV detection methods: ExomeDepth (Plagnol et al., 2012) , CoNVaDING (Johansson et al., 2016) , VisCap (Pugh et al., 2016) , NextGENe (Softgenetics, State
College, PA), and SeqNext (JSI Medical Systems GmbH, Kippenheim, Germany).
MATERIALS AND METHODS

panelcn.MOPS pipeline
Input
The panelcn.MOPS pipeline uses BAM files as input. A BED file is needed to specify the ROIs that constitute the count windows.
Alternatively, a matrix of RCs can be used directly as input to the panelcn.mops algorithm. For our analyses, each ROI consisted of a coding exon ±31 nucleotides of flanking intronic sequences leading to ROIs with a size between 67 and 6,636 bp. Although it was not used for the reported results, larger exons can be split into multiple overlapping ROIs in order to increase the resolution of the CNV detection algorithm.
Read counting
We adapted the read counting procedure of the R package exomeCopy (Love et al., 2011) for NGS panel data: all reads that overlap with the current ROI are counted with paired reads being handled separately.
A fixed read length of 150 bp was assumed throughout the analysis because in tests on the validation set this achieved more robust results than the true read length for each read. However, the read length is a parameter that needs to be set by the user according to the specifications of the data used. 
QC
Normalization
Each sample's RCs are scaled such that the total number of reads are comparable across samples. The best performance was achieved by normalizing to the third quartile, which is equivalent to the upper quartile normalization (Bullard, Purdom, Hansen, & Dudoit, 2010) , and rescaling with the first quartile of the scaling factors.
CN detection
The raw CNV detection algorithm of the cn.mops R package is applied to each ROI separately. In order to increase sensitivity, we adapted the expected fold change of the CN classes. According to our results on the validation set (see section "TSC panel validation set"), we set the parameter to 0.57 for CN1 (deletion) and to 1.46 for CN3 (duplication).
Segmentation
We tried various segmentation algorithms. However, for the pipeline to be able to detect CNVs that affect only a single ROI or even just part of a ROI, omitting the segmentation step leads to better results.
Filtering for genes of interest
In clinical settings, the analysis of only a subset of genes covered by the panel is frequently requested. Therefore, any results concerning the remaining genes should be masked to avoid incidental findings.
Accordingly, we implemented a function that presents results only for user-specified genes while using the RCs of all genes to compute the CNs, which offers several advantages (see section "Whole-gene CNVs").
If all genes of the panel are of interest, no filtering is performed and results for all genes are displayed.
Output
In addition to a table of results, panelcn.MOPS creates boxplots of the normalized RCs of each ROI of a user-specified gene for visual inspection (see Fig. 2 ).
Graphical user interface
We do not only offer panelcn.MOPS as an R package, but also provide a simple GUI with an easy-to-use installer. As the implementation is based on a combination of R shiny (Chang, Cheng, Allaire, Xie, & McPherson, 2016) and R portable (Redd & Huber, 2010) , it does not require any additional programs to be installed by the user. test set were evaluated separately because they had CNVs smaller than one ROI (small CNVs dataset). Three samples were excluded from further analysis because they contained de novo ALU insertions (Wimmer, Callens, Wernstedt, & Messiaen, 2011) . Nevertheless, all seven samples were used as controls for the rest of the samples.
Samples
In order to extend our study to a different NGS panel, we created a set of 10 additional cases processed on a customized panel (Nextera Rapid Capture; Illumina) targeting 117 genes in the following referred to as Custom Panel.
Library preparation and sequencing
Adapter-tagged libraries were prepared according to the TruSight TM Rapid Capture workflow (Illumina) using a transposase-based method (Nextera) (Marine et al., 2011) . Sequencing was performed on a MiSeq instrument following the Illumina 300 sequencing cycle program with paired-end reads. For more details, see Supp. Methods.
Sequence alignment
Only the commercial tools NextGENe and SeqNext use FASTQ files directly as input. For methods, which require BAM files as input, sequence alignment to human reference genome build b37 with BWA version 0.7.12 (Li & Durbin, 2009 ) was followed by removal of duplicates and fixing of mate information with SAMtools version 0.1.19 . Afterwards, local realignment around indels and base quality score recalibration was performed with the Genome Analysis Tool Kit (GATK) version 3.5 (McKenna et al., 2010) . Supp. Table S3 shows the total number of raw and mapped reads for each sample. For
VisCap, DepthOfCoverage files were also generated with GATK version 3.5. The BED files used throughout the analysis comprised all coding exons ±31 nucleotides of flanking intronic sequences.
We performed additional tests with changes in the alignment process to check how panelcn.MOPS depends on these settings. Omitting the postprocessing steps of GATK did not affect the RCs of the genes of interest and therefore panelcn.MOPS reported exactly the same CNs.
Using BWA-MEM (Li & Durbin, 2009) 
Controls
Except for NextGENe, which can handle only 10 control samples, the 
Evaluation criteria
In each sample, each ROI was classified as positive if it was affected by a CNV, and as negative otherwise. ROIs marked as low quality by a method were considered as no-call for that method and removed prior to sensitivity and specificity calculation. For a low-quality sample, 
Restriction to genes of interest
RESULTS
TSC panel validation set
The parameter settings of all methods were optimized on the 25 samples of the validation set. The aim was to find an optimal trade-off between highest sensitivity and a low number of FPs as well as good QC settings. One sample (IBK42) was labeled as low quality by all methods. Other samples were marked as low quality by only one or two methods (see Supp. Table S1 ). For panelcn.MOPS and CoNVaD-ING, we were able to adjust the parameters such that both methods achieved 100% sensitivity and specificity. panelcn.MOPS reported only An inherent weakness of the tested version of NextGENe and
SeqNext is the failure to report deletions of all ROIs of a single gene of interest, for example, the deletion of the whole NF1 gene in three samples where NF1 was the only gene analyzed. Furthermore, neither CNV detection program was able to detect the above-mentioned small deletion (IBK9). Additionally, we were unable to define parameters for NextGENe that avoided one false positive duplication (IBK25) without creating FNs, and hence losing sensitivity.
TSC panel test set
Using the best parameters as determined on the validation set (see Supp. Methods), we evaluated the performance of all six methods on a test set of 138 samples as described in the section "Evaluation cri-
teria." Table 1 shows the sensitivities, specificities, and no-call rates of all methods. panelcn.MOPS achieved 100% sensitivity and specificity while the no-call rate was 0.04. This means that 4% of ROIs were marked as low quality because either the whole sample or the ROI was of low quality. Both CoNVaDING and SeqNext missed only a single positive ROI with CoNVaDING additionally reporting one FP (see Supp. Table S1 ). Both had no-call rates similar to that of panelcn.MOPS. As
ExomeDepth lacks a QC criterion for ROIs, it did not flag any ROI as low quality. Consequently, ExomeDepth had a high number of FPs, and thus low specificity. Also, NextGENe achieved a low no-call rate at the expense of low specificity. VisCap exhibited low specificity, although it had the highest no-call rate.
Small CNVs
In order to explore the limits of the methods compared, we tested whether CNVs smaller than a ROI could be detected (see Supp. Table   S1 ). Although CNVs are often defined as deletions or duplications larger than 50 bp, we also consider smaller ones. Since we only used Table S1 ).
Custom panel
Runtime
The runtimes of the different programs were determined by running the CNV detection algorithm itself five times on all 170 TSC panel samples and calculating the median. The time for creating BAM files or calculating RCs was not considered since these procedures must be performed only once for each file. Subsequently, the precalculated RCs can be used directly by the programs. The runtime calculations were performed on an Intel i5-4300U CPU with 8 GB of RAM. The median runtime of panelcn.MOPS was less than 9 min, followed closely by ExomeDepth with 13 min, whereas VisCap was considerably slower with 2.5 hr. CoNVaDING was by far the slowest with a median runtime of 7 hr and 50 min. Since NextGENe and SeqNext can only be used via the GUI, calculating the runtime is not straightforward. NextGENe cannot handle more than one sample at a time; however, since the analysis of a single sample takes more than 1 min, analyzing 170 samples takes several hours. As SeqNext performs variant calling and CNV detection in a single run, it is not possible to determine the runtime of the CNV detection algorithm alone. However, the whole analysis takes several hours.
DISCUSSION
Nearly all methods yielded similarly high sensitivity and specificity, but panelcn.MOPS led the field. However, the following aspects are also important (see Fig. 3 ).
QC
Differences in quality and amount of DNA, or measurement noise may render the RCs of affected samples incomparable and can lead to FPs. exons 12-15 known to be problematic due to the highly homologous pseudogene PMS2L (Ganster et al., 2010; van der Klift et al., 2010; Vaughn, Baker, Samowitz, & Swensen, 2013) . For the custom panel, most FPs were caused by CYP21A2 and its pseudogene CYP21A1P (New & Wilson, 1999) . These FPs are avoided by panelcn.MOPS, CoNVaDING, and SeqNext since the ROIs are recognized as low quality. Overall, the methods with the best balance between low no-call rate and sufficient QC were panelcn.MOPS and SeqNext. All other methods either lacked QC for ROIs and/or excluded too many samples, which resulted in a low specificity and/or a high nocall rate.
Small CNVs
We were interested in the methods' limitations for CNVs smaller than one ROI. Remarkably, most of the methods identified a deletion of only 20 bp, which would technically not be considered a CNV.
However, duplications are harder to identify and so not all of the small CNVs were detected. Our tests have shown that a sensitive F I G U R E 3 Strengths and weaknesses of all methods analyzed. In general, "+++" indicates the best possible performance, whereas "++" means the method is close to the best, "+" is acceptable, but not very good, and "−" signals failure or missing feature. For the two detection performance measures (i.e., sensitivity and specificity), 100% is indicated by "+++." A single FN or FP is indicated by "++" in the corresponding sensitivity or specificity row. More than one false classification but an overall sensitivity or specificity greater than 95% is indicated by "+." "No-call rate" stands for the fraction of ROIs classified as low quality (see the section "Evaluation criteria"). "+++" means no-call rate of 0, "++" means less than 0.01, "+" means less than 0.1, and "−" means no-call rate larger than 0.1. Programs with QC for samples and ROIs are marked as "+++," whereas programs with QC only for samples are marked as "+." For "CNVs <1 ROI," each plus sign symbolizes one successful detection of a CNV that affected only part of a ROI (see the section "Small CNVs"). The row "Whole-gene CNVs" especially concerns CNVs that affect all ROIs that are within the gene of interest for a patient. "+++" indicates that all of them were detected, whereas "++" indicates that some of them were detected and others classified as low quality. If the CNVs affecting the entire gene of interest are not fully detected, this is indicated by "+," whereas "−" means that these CNVs can only be detected while risking incidental findings. While "+" in the row "Incidental findings" indicates that incidental findings can be avoided, but only at the risk of missing CNVs that affect all ROIs analyzed, "+++" means that the method avoids incidental findings without loss of power. "−" reflects that the CNV tool offers no option to filter the results for genes of interest and, therefore, for avoiding incidental findings. The row "Runtime" indicates the runtime of the CNV detection algorithm measured as described in the section "Runtime." The thresholds for "+++," "++," "+," and "−" are less than 10 min, less than 1 hr, less than 6 hr, and more than 6 hr, respectively. Classes for the row "GUI" are: "+++" if there is an easy-to-use graphical user interface (GUI), "++" if the GUI is not easy to use, and "−" if there is no GUI at all. Since only two of the programs are commercial, they were marked "−" in the corresponding row, whereas all others have "+++"
variant calling program such as that of SeqNext is able to detect the CNVs smaller than one ROI, and in contrast to CNV detection methods can also define the exact breakpoints. Therefore, the CNV detection methods should be rather used as an additional confirmation tool and not as a primary identification tool for these small CNVs. Table   S1 ). Only panelcn.MOPS and ExomeDepth (with our additional filter for genes of interest) were able to find all whole-gene deletions without risking incidental findings.
Whole-gene CNVs
Incidental findings
Many gene panels contain genes that are relevant for different diseases. For each patient, only a specific set of these genes is of interest and no information concerning other genes should be reported. 
Controls
Some of the methods compared are highly dependent on the controls.
Since NextGENe accepts a maximum of only 10 controls, the developers suggest using samples of the same sequencing run as they are likely to show the same sequencing characteristics. However, the controls have to be chosen carefully, such that they do not harbor the same 
Runtime
If only a small number of samples is analyzed, a runtime of a few minutes per sample does not pose a big problem. However, in a larger setting such as ours with more than 100 samples, this means hours rather than minutes. For NextGENe, there is an additional issue: it does not support the analysis of more than one sample at a time; therefore, in addition to a runtime of several hours, the hands-on time is longer than for the other methods. Since calculating CNs for a single sample takes only seconds with panelcn.MOPS, large datasets with thousands of samples can be analyzed within hours rather than days. 
Graphical user interface
Usage with different types of data
CONCLUSIONS
In this first thorough comparison of six state-of-the-art CNV detection methods for targeted NGS panels, we have demonstrated that panelcn.MOPS has not only the highest sensitivity and specificity, but also one of the best QCs. Furthermore, panelcn.MOPS uses reads from all ROIs to determine the CN, but exclusively presents results for user-selected genes avoiding incidental findings. The freely available panelcn.MOPS can readily be used via the GUI by clinical geneticists without programming experience, or integrated as R package into existing variant detection pipelines.
